Related references
Note: Only part of the references are listed.Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia
Mai F. Alsaqa'aby et al.
ANNALS OF SAUDI MEDICINE (2017)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPEAN HEART JOURNAL (2016)
Saudi Atrial Fibrillation Survey: National, Observational, Cross-sectional Survey Evaluating Atrial Fibrillation Management and the Cardiovascular Risk Profile of Patients With Atrial Fibrillation
Ahmad Hersi et al.
ANGIOLOGY (2015)
Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
Thitima Kongnakorn et al.
CLINICAL DRUG INVESTIGATION (2014)
Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
Gregory Y. H. Lip et al.
CLINICAL THERAPEUTICS (2014)
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
Paul Dorian et al.
EUROPEAN HEART JOURNAL (2014)
Updating Cost-Effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold
Peter J. Neumann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin
T. Lanitis et al.
JOURNAL OF MEDICAL ECONOMICS (2014)
The Global Burden of Atrial Fibrillation and Stroke A Systematic Review of the Epidemiology of Atrial Fibrillation in Regions Outside North America and Europe
Gregory Y. H. Lip et al.
CHEST (2012)
2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2006 WRITING COMMITTEE MEMBERS Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Valentin Fuster et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Catalogue of EQ-5D Scores for the United Kingdom
Patrick W. Sullivan et al.
MEDICAL DECISION MAKING (2011)
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
A. John Camm et al.
EUROPEAN HEART JOURNAL (2010)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
S. J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Antithrombotic therapy in atrial fibrillation
Daniel E. Singer et al.
CHEST (2008)
The NICE cost-effectiveness threshold - What it is and what that means
Christopher McCabe et al.
PHARMACOECONOMICS (2008)
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Scott D Grosse
Expert Review of Pharmacoeconomics & Outcomes Research (2008)
Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study
S Stewart et al.
HEART (2001)
Prevalence of diagnosed atrial fibrillation in adults - National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
AS Go et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
